APA (7th ed.) Citation

JE, L., A, F., D, Y., C, Y., D, W., J, P., . . . LJ, E. (2022). Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. NPJ breast cancer, 8(1), 128. https://doi.org/10.1038/s41523-022-00493-z

Chicago Style (17th ed.) Citation

JE, Lang, et al. "Safety and Efficacy of HSP90 Inhibitor Ganetespib for Neoadjuvant Treatment of Stage II/III Breast Cancer." NPJ Breast Cancer 8, no. 1 (2022): 128. https://doi.org/10.1038/s41523-022-00493-z.

MLA (9th ed.) Citation

JE, Lang, et al. "Safety and Efficacy of HSP90 Inhibitor Ganetespib for Neoadjuvant Treatment of Stage II/III Breast Cancer." NPJ Breast Cancer, vol. 8, no. 1, 2022, p. 128, https://doi.org/10.1038/s41523-022-00493-z.